Zacks: Brokerages Expect OraSure Technologies, Inc. (NASDAQ:OSUR) to Announce $0.03 Earnings Per Share

Equities analysts predict that OraSure Technologies, Inc. (NASDAQ:OSUR) will announce earnings per share of $0.03 for the current quarter, according to Zacks. Three analysts have issued estimates for OraSure Technologies’ earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.05. OraSure Technologies reported earnings of ($0.10) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 130%. The firm is expected to report its next earnings results on Wednesday, May 5th.

On average, analysts expect that OraSure Technologies will report full-year earnings of $0.65 per share for the current fiscal year, with EPS estimates ranging from $0.04 to $1.73. For the next fiscal year, analysts expect that the firm will report earnings of $0.80 per share, with EPS estimates ranging from $0.08 to $2.39. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Monday, March 1st. The medical instruments supplier reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). The business had revenue of $62.90 million for the quarter, compared to the consensus estimate of $57.30 million. OraSure Technologies had a negative return on equity of 3.51% and a negative net margin of 9.05%. OraSure Technologies’s revenue was up 26.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.04 earnings per share.

OSUR has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 3rd. Citigroup reduced their price objective on shares of OraSure Technologies from $18.00 to $16.00 in a report on Tuesday, March 2nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. OraSure Technologies presently has an average rating of “Buy” and an average target price of $16.71.

Shares of NASDAQ:OSUR traded down $0.13 during midday trading on Friday, reaching $10.32. 4,059 shares of the company’s stock were exchanged, compared to its average volume of 1,126,327. The company’s 50 day simple moving average is $11.11 and its two-hundred day simple moving average is $12.57. The firm has a market capitalization of $742.48 million, a PE ratio of -45.43 and a beta of 0.04. OraSure Technologies has a 12 month low of $9.46 and a 12 month high of $19.75.

A number of hedge funds and other institutional investors have recently modified their holdings of OSUR. AdvisorNet Financial Inc acquired a new position in OraSure Technologies during the 4th quarter valued at about $26,000. ProShare Advisors LLC acquired a new position in OraSure Technologies during the 3rd quarter valued at about $122,000. Hsbc Holdings PLC acquired a new position in OraSure Technologies during the 4th quarter valued at about $122,000. Highlander Capital Management LLC acquired a new stake in shares of OraSure Technologies in the 4th quarter valued at approximately $148,000. Finally, Cornerstone Investment Partners LLC acquired a new stake in shares of OraSure Technologies in the 4th quarter valued at approximately $157,000. Institutional investors and hedge funds own 98.13% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: Black Swan

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.